The core issue here is urgent: researchers worry that NIH’s plan to cap or limit publication fees could overshadow the real costs of disseminating science, potentially hindering access to high-quality journals and stifling early-career researchers. But here’s where it gets controversial: major research groups say the proposed caps misjudge who actually controls those costs and could shift the burden onto other parts of the research ecosystem.
The National Institutes of Health recently invited public input on its ideas to curb how grant funds are spent on publishing research. In its run-up to a final policy, NIH reviewed comments from July 30 to September 15. The feedback highlighted a broad consensus among prominent advocacy groups and institutions that the suggested caps, particularly on article processing charges (APCs), are not well calibrated to the realities of publishing costs. The Association of American Medical Colleges, the Association of Public and Land-grant Universities, the Association of American Universities (AAU), and COGR jointly urged NIH to pursue approaches that recognize that neither research institutions nor individual investigators control APCs; publishers own those costs. They described the proposed caps as arbitrary and asked NIH to consider waivers and a generous transition period—ideally at least a year—to help universities adjust budgets and negotiate with publishers.
These arguments come from a quartet of influential entities. The AAU represents leading research universities, while COGR focuses on federal-level advocacy for researchers and universities. They assert that APCs are set by publishers and that NIH’s cap plan would not address the underlying dynamics of pricing in scholarly publishing.
In their view, the average NIH grant last year was around $620,000, with roughly seven publications produced per grant. They estimate that the average APC for journals where NIH-funded researchers publish is near $4,000, meaning about $28,000 in APCs per grant—almost 4.3 percent of a typical award, not the 0.8 percent the NIH proposed. They warn that a cap could disproportionately burden less-well-funded institutions and early-career researchers, potentially pushing scholars toward lower-cost journals or in extreme cases to publish with journals that skip peer review—an outcome that would raise serious quality and credibility concerns for biomedical and health research.
Other voices, including the American Psychological Association, caution that revenue pressures might drive publishers to raise prices to the new threshold or to consolidate power, benefiting large for-profit publishers at the expense of nonprofits. They suggest that established researchers with access to alternative funding could still publish in higher-cost venues, while early-career researchers and those from resource-strapped institutions would bear the brunt of any caps. The APA also warned that caps could encourage the industry to favor volume over rigorous peer review, potentially compromising scholarly quality.
Representatives from the Big Ten Academic Alliance’s research libraries, which collectively produce a sizable share of U.S. research output, echoed similar concerns. They argued that APCs don’t reflect actual publishing costs and that caps could wind up transferring costs elsewhere in the taxpayer-funded research system. They warned that lower caps might push journals to publish more articles at the expense of editorial quality, and they cautioned that profit-oriented publishers will find ways to justify higher fees by any means, especially without transparent cost data.
In response, NIH emphasizes that public feedback underscores the importance of the issue. A spokesperson noted that the agency is thoroughly reviewing all input as it continues shaping policy and that a preferred option or a concrete timeline has not yet been determined.
Bottom line: the debate centers on how to balance fair access to published research with the financial realities of high-quality, rigorous peer review. If caps are implemented without accounting for actual costs and transitional needs, there’s a risk of pushing researchers toward less reputable venues or constraining innovation—especially for those with fewer resources. Do you think NIH should cap APCs at a fixed percentage of direct costs, set a hard dollar ceiling, or pursue another approach entirely? What safeguards would you propose to protect early-career researchers and smaller institutions while maintaining high editorial standards and broad access to findings?
